Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3076-3081

  Kim, Tae Won ^a   Lee, Hyoungnam ^a   Kang, Yoon Koo ^a,b   Choe, Mi Sun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Kim, Jung Sun ^a   Yook, Jeong Hwan ^a   Kim, Byung Sik ^a   Lee, Jung Shin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; STEM CELL FACTOR;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS; MULTIVARIATE ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SPINDLE CELL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SEQUENCE HOMOLOGY, AMINO ACID; STROMAL CELLS;

EID: 2442551759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0581     Document Type: Article

References (25)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
2. Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results, and does it make any difference? Monogr Pathol 1990;31:220-46.
3. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103:41-7.
4. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
5. Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997;28:160-5.
6. Tornoczky T, Kalman E, Hegedus G, et al. High mitotic index associated with poor prognosis in gastrointestinal autonomic nerve tumour. Histopathology 1999;35:121-8.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash. DC) 1998;279:577-80.
8. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
9. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
10. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-10.
11. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-5.
12. Kinoshita K, Isozaki K, Hirota S, et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003;18:147-51.
13. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-300.
14. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Investig 1998;78:1633-6.
15. Fletcher CD, Berman JJ, Curless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
16. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
17. Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′-end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003;16:1257-64.
18. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003;34:1306-12.
19. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001;92:494-8.
20. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
21. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
22. Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999;18:1897-902.
23. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
24. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science (Wash. DC) 2003;299:708-10.
25. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.